Drug intelligence / Profile preview

OCT-50

Development stage: Preclinical
Lead developer: Octagon Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

OCT-50 is a monoclonal antibody drug candidate targeting CD22, a cell surface molecule primarily expressed on B cells. Its mechanism of action involves modulation of CD22, which plays a role in regulating immune responses. The drug is being developed by Octagon Therapeutics for potential use in immune system diseases (such as lupus erythematosus and Sjogren's syndrome), nervous system diseases (including multiple sclerosis), and eye diseases. As of the latest update, OCT-50 remains in preclinical development and has not yet entered clinical trials or received regulatory approval[2].

Targets

CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on OCT-50.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCT-50.

Explore the full profile